HIV-1 remains a global health crisis, with approximately 40 million people living with the virus worldwide. Despite progress in managing the disease through antiretroviral therapy, challenges such as drug resistance, side effects, and social stigma persist, underscoring the urgent need for new therapeutic strategies. Integrase, long recognized for its function in inserting viral DNA into the infected host’s genome, has now been found to also engage viral RNA at later stages—highlighting previously uncharacterized roles in the HIV lifecycle.

The Salk research team employed cryo-electron microscopy (cryo-EM) to capture integrase in two distinct structural conformations. Initially, integrase operates as part of a massive “intasome” complex, consisting of four identical subunits arranged into a 16-part assembly. This architecture tightly encircles viral DNA, orchestrating its integration into the host genome, a critical step that establishes permanent infection within the host cell.

Later in the replication process, integrase adopts a drastically different form. It transitions from the large intasome to a minimalist four-part complex, a configuration associated with binding to viral RNA inside the HIV capsid. This structural transition from DNA-focused activity to RNA interaction reveals the protein’s adaptability and suggests additional layers of complexity in HIV’s replication machinery.

This discovery marks the first time researchers have visualized integrase’s RNA-bound state, providing a high-resolution blueprint for this elusive form. Such structural insights are invaluable, as the design of targeted inhibitors typically relies on detailed knowledge of a protein’s 3D configuration to effectively disrupt its function without off-target effects.

The implication of integrase functioning beyond DNA integration is profound. While current integrase inhibitors such as Dolutegravir effectively block the protein’s DNA integration role, HIV’s rapid mutation rate often leads to resistance. By targeting integrase’s secondary role in RNA interaction, drug developers may circumvent existing resistance mechanisms, opening the door to new classes of antiretroviral therapies.

Senior author Dmitry Lyumkis, PhD, emphasizes the significance of these findings: “We are only beginning to understand the multifunctionality of integrase proteins. Mapping its interaction with RNA not only enriches our knowledge of viral biology but also informs the rational design of next-generation HIV therapeutics.”

At the molecular level, HIV’s retroviral replication strategy involves reverse-transcribing its RNA genome into DNA, which is then inserted into the host’s genome via integrase. This insertion transforms the host cell into a viral factory, producing progeny RNA that is packaged for new infections. Understanding the full scope of integrase’s roles in this cycle is essential for developing comprehensive antiviral strategies.

The integrase’s structural plasticity uncovered by the Salk team illustrates the dynamic nature of viral proteins. Their data show how subtle shifts in quaternary structure—disassembling from a 16-subunit “lock” to a compact 4-subunit complex—enable integrase to pivot between its DNA and RNA binding functions. Such dynamic assembly-disassembly processes could be exploited pharmacologically to trap the protein in inactive states.

This research represents a collaboration among numerous experts across molecular biology, structural biology, and virology, including significant contributions from partnering institutions such as the University of Colorado School of Medicine, Dana-Farber Cancer Institute, and the National Institute of Diabetes and Digestive and Kidney Diseases. Their collective expertise underscores the complexity and interdisciplinary nature of combatting HIV.

The study also showcases the power of cryo-electron microscopy, which has revolutionized structural biology by enabling the visualization of large and flexible protein complexes in near-native states. The high-resolution cryo-EM maps generated by the researchers provide unparalleled detail into integrase’s architecture, setting a new standard for future investigations of viral proteins.

Beyond its scientific merit, this discovery carries translational potential for public health. Novel integrase inhibitors targeting both DNA and RNA-related functions may reduce drug resistance, improve treatment durability, and mitigate adverse effects. Such advances are critical in the ongoing global effort to curb HIV transmission and improve the quality of life for millions affected by the virus.

As the scientific community digests these findings, follow-up studies are anticipated to confirm integrase’s RNA interaction mechanisms, assess their roles in viral encapsidation and infectivity, and explore the potential for targeting these interactions therapeutically. This evolving picture of integrase’s biology promises to reshape HIV drug development paradigms in the coming years.

The Salk Institute’s pioneering research not only deepens our fundamental understanding of HIV biology but also exemplifies the fusion of structural insights and therapeutic innovation. With new blueprints in hand, drug designers are now better equipped than ever to develop integrase-targeting agents that could transform the clinical management of HIV-1 infection and ultimately help turn the tide against this enduring pandemic.

Subject of Research: Structural and functional analysis of HIV-1 integrase in its dual roles interacting with viral DNA and RNA.

Article Title: Structural Elucidation of HIV-1 Integrase Reveals Dual Functionality in Viral DNA Integration and RNA Interaction

News Publication Date: October 24, 2025

Web References:
https://www.nature.com/articles/s41467-025-64479-8

References:
Lyumkis, D., Jing, T., Shan, Z., et al. (2025). Structural insights into HIV-1 integrase functions during DNA integration and RNA interaction. Nature Communications. DOI: 10.1038/s41467-025-64479-8

Image Credits:
Salk Institute

Traditional oral antiretroviral therapy (ART) regimens, although effective, face pervasive challenges including pill fatigue, stigma associated with daily medication, and suboptimal adherence. These obstacles contribute substantially to viral rebound and the emergence of drug resistance. The introduction of long-acting injectable agents offers a paradigm shift by drastically reducing dosing frequency from daily tablets to monthly or even less frequent clinic visits. Lenacapavir, a first-in-class capsid inhibitor with extended half-life properties, when combined with cabotegravir, an integrase strand transfer inhibitor also formulated for long-acting delivery, creates a potent, synergistic duo that maintains therapeutic drug levels over prolonged periods.

The study employs sophisticated epidemiological modeling integrated with economic analyses to simulate the impact of deploying this injectable combination throughout various African settings characterized by diverse HIV epidemiology, healthcare infrastructure, and socio-economic factors. By operating within real-world constraints, the research presents a nuanced picture of how such a regimen could alter HIV incidence and prevalence through improved adherence, reduced transmission, and enhanced viral suppression rates. Importantly, it quantifies not only clinical outcomes but also health system costs and cost-effectiveness, a critical consideration for policy implementation in countries with limited healthcare budgets.

One of the most compelling aspects underscored in the study is the potential for long-acting injectable therapy to alleviate the adherence burden that compromises conventional ART success. The monthly or bimonthly administration, often directly observed in clinical settings, minimizes the risk of missed doses and the consequent viral rebound. This approach is particularly advantageous for populations facing structural barriers—such as rural residents, key populations experiencing stigma, and individuals with unpredictable lifestyles. By improving retention in care, the injectable regimen could substantially suppress community viral loads, thereby reducing onward HIV transmission at a population level.

Lenacapavir occupies a unique space mechanistically; as a capsid inhibitor, it disrupts the viral capsid’s integrity and lifecycle, targeting multiple stages from capsid stabilization and nuclear import of the viral genome to assembly and release of new virions. This multifaceted mechanism diminishes the likelihood of resistance emergence. When partnered with cabotegravir—which inhibits integration of viral DNA into the host genome—this dual formulation operates on complementary viral processes, enhancing antiviral potency and reducing the probability of treatment failure.

The modeling framework integrates data from clinical trials, demographic surveillance, and real-world adherence studies, allowing projections over extended timelines. By simulating scenarios with varying degrees of regimen uptake and retention, the analysis reflects realistic implementation pathways. Cost components considered include drug acquisition, administration infrastructure, laboratory monitoring, and clinic visits. Compared against standard oral ART, the injectable combination demonstrates favorable incremental cost-effectiveness ratios in most modeled contexts, indicating good value for money within widely recognized cost-effectiveness thresholds.

Beyond economics and efficacy, the study addresses potential implementation challenges, emphasizing the need for robust supply chains, healthcare worker training, and patient education. Vaccine-like delivery models could be explored to streamline administration, while decentralized distribution points may enhance accessibility in remote areas. Ethical considerations, including equitable access and consent processes for injectable therapies, are paramount to ensure the benefits percolate across all strata of affected populations.

Moreover, by reducing regimen complexity and enhancing convenience, this injectable strategy may also indirectly reduce HIV-associated stigma. The discrete nature of clinic-based injections can circumvent the daily visibility of pill-taking and minimize medication-related reminders, which often pose psychological and social barriers. Enhanced confidentiality may encourage earlier initiation of treatment, improving individual health outcomes and epidemiologic control.

The timing of this study is particularly auspicious, as global HIV control efforts strive to meet the UNAIDS 95-95-95 targets—95% of people living with HIV knowing their status, 95% of those diagnosed receiving sustained ART, and 95% of those on ART achieving viral suppression. By potentially elevating viral suppression rates through improved adherence, lenacapavir plus cabotegravir injectable therapy could be an essential tool to accelerate progress toward epidemic control goals in sub-Saharan Africa, home to the majority of the world’s HIV burden.

It is also important to recognize the role of scientific innovation in expanding therapeutic options for complex chronic infections such as HIV. The development of novel molecules with extended half-lives challenges traditional daily pill regimens and paves the way for combination formulations tailored for long-term, simplified administration. Such advancements echo broader trends in infectious disease management and personalized medicine, underscoring how pharmacologic chemistry, virology, and health economics converge to craft sustainable global health interventions.

Furthermore, the potential scalability of this intervention holds promise for health systems severely strained by high patient volumes and logistical challenges. Reduced frequency of drug dispensing decreases healthcare worker workload and clinic congestion, freeing resources for other critical services. The injectable approach could synergize with other prevention strategies including pre-exposure prophylaxis (PrEP), voluntary medical male circumcision, and expanded testing initiatives, creating a comprehensive, multilayered response to HIV transmission dynamics.

Despite the enthusiasm, the authors caution against premature broad-scale deployment before addressing open questions such as long-term safety, resistance surveillance, and cost negotiations with pharmaceutical manufacturers. Equitable pricing and inclusion of marginalized populations in roll-out plans are indispensable to prevent exacerbating health disparities. Moreover, integration with existing ART programs requires careful coordination to avoid disruption of established patient care pathways.

In the landscape of HIV therapeutics, where incremental gains matter immensely, this study’s insights illuminate a promising future wherein sustained viral control is achievable through innovative drug delivery mechanisms. The prospect of a once-monthly injectable that combines formidable pharmacodynamics with cost-effectiveness could redefine treatment accessibility, adherence, and ultimately, the course of the HIV epidemic in Africa.

In summary, this comprehensive examination of long-acting injectable lenacapavir plus cabotegravir therapy underscores the potential for a paradigm-shift in HIV treatment, especially within the African context. By demonstrating that enhanced adherence facilitated by reduced dosing frequency can translate into both improved clinical outcomes and economic efficiency, the research lays a solid foundation for future policy decisions. As the global health community races to end the HIV epidemic, such innovations illuminate a path toward equitable and effective care.

Subject of Research: The potential impact and cost-effectiveness of long-acting injectable lenacapavir combined with cabotegravir as HIV treatment in Africa.

Article Title: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa.

Article References:
Phillips, A., Smith, J., Bansi-Matharu, L. et al. Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa. Nat Commun 16, 5760 (2025). https://doi.org/10.1038/s41467-025-60752-y

Image Credits: AI Generated